ABOUT
Building the future of early disease detection through AI and proteomics
Eliptica brings together expertise across diagnostics, clinical translation, mass spectrometry, machine learning and company building to develop future blood-based tests for early disease detection.
100+ years
Combined experience across life sciences, diagnostics and technology
Proteomics + AI
Scientific and technical leadership across plasma proteomics, mass spectrometry and AI.
Clinical translation
Focused on moving discovery towards future blood-based testing
Management and Board
Supported by an interdisciplinary team spanning proteomics, AI, engineering, biology, clinical translation and operations.
CEO
Charles Brigden
Leads company strategy, partnerships and translation towards future clinical testing.
Read bio
CSO
Markus Ralser
Scientific leader in metabolism, proteomics and technology development.
Read bio
CTO
Aleksej Zelezniak
Leads AI strategy, data infrastructure and predictive modelling.
Read bio
Board Member
Garry Kruppa
Senior industry expert in mass spectrometry, proteomics and translational diagnostics.
Read bio
Partners
Working with leading organisations across research, healthcare and technology.
OUR LOCATION
Based in London
Eliptica is based in London, within one of Europe’s leading ecosystems for cancer research, diagnostics and translational medicine.
Eliptica Ltd, The London Cancer Hub, Cotswold Road, London SM2 5NG